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Despite the increasing use of humanized mouse models to study new approaches of
graft-versus-host disease (GVHD) prevention, the pathogenesis of xenogeneic GVHD
(xGVHD) in these models remains misunderstood. The aim of this study is to describe
this pathogenesis in NOD/LtSz-PrkdcscidIL2rγtm1Wjl (NSG) mice infused with human
PBMCs and to assess the impact of the expression of HLA-A0201 by NSG mice
cells (NSG-HLA-A2/HHD mice) on xGVHD and graft-versus-leukemia (GvL) effects, by
taking advantage of next-generation technologies. We found that T cells recovered from
NSG mice after transplantation had upregulated expression of genes involved in cell
proliferation, as well as in TCR, co-stimulatory, IL-2/STAT5, mTOR and Aurora kinase
A pathways. T cells had mainly an effector memory or an effector phenotype and
exhibited a Th1/Tc1-skewed differentiation. TCRβ repertoire diversity was markedly lower
both in the spleen and lungs (a xGVHD target organ) than at infusion. There was no
correlation between the frequencies of specific clonotypes at baseline and in transplanted
mice. Finally, expression of HLA-A0201 by NSG mice led to more severe xGVHD and
enhanced GvL effects toward HLA-A2+ leukemic cells. Altogether our data demonstrate
that the pathogenesis of xGVHD shares important features with human GVHD and that
NSG-HLA-A2/HHD mice could serve as better model to study GVHD and GvL effects.
Keywords: GVHD, xenogeneic, NSG, NSG-HLA-A2/HHD, TCR receptor, TCRβ repertoire, RNA sequencing, graft-
versus-leukemia
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HCT) offers potential curative treatment
for a wide range of hematological disorders (1). In patients with hematological malignancies,
tumor eradication depends both on the conditioning regimen given before allo-HCT, and on graft-
versus-leukemia (GvL) effects mediated by donor immune cells (mainly T cells) contained in the
graft (2–4). Unfortunately, donor T cells can also attack healthy tissues of the recipient, causing
graft-versus-host disease (GVHD), a life-threatening complication of allo-HCT (5–7).
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GVHD pathogenesis has been mostly studied in mouse-to-
mouse models of transplantation (8–12). However, these models
of GVHD have some caveats such as: (1) fixed genetic and
immunologic disparities between donor and recipient within a
determined murine GVHD model; (2) the uniform use of young
adult mice (in contrast to the increasing use of allo-HCT in
older patients/donors); (3) the fact that mice are housed from
birth to death under pathogen-free conditions while donors
and patients are exposed before and after transplantation to
pathogens than can affect their immune responses (13, 14); and
(4) important divergences betweenmurine and human immunity
(15–17).
In the last decades, humanized murine models of xenogeneic
GVHD (xGVHD) have been developed (18). Among these, the
“NSG xGVHD murine model” consisting of injection of human
peripheral blood mononuclear cells (hPBMC) into NOD/LtSz-
PrkdcscidIL2rγtm1Wjl (NSG) mice is increasingly used (19–30).
NSG mice combine the lack of T-cell and B-cell activity of the
SCID mice and the reduced macrophage activity of the NOD
mice with the absence of NK activity due to the absence of the
expression of the IL2rγ. Consequently, low doses of hPBMC
consistently engraft in these mice even without prior irradiation,
although irradiation significantly increases xGVHD severity (19–
22).
In comparison to mouse-to-mouse models of GVHD, the
NSG “humanized” model has some advantages such as the use
of human cells to induce and control xGVHD, the possibility
to use donors with a high genetic diversity, and the possibility
to use older donors previously exposed to various pathogens.
However, the pathogenesis of xGVHD induced by injection of
hPBMCs in NSG mice has been only partly elucidated. It has
been established that human T cells are able to recognize murine
xeno-antigens presented by murine major histocompatibility
complex (MHC) (31). Further, human CD28 receptor is able to
interact with murine B7.2 molecules thus providing a second
signal for human T cells (32). In accordance with these prior
observations, it has been elegantly demonstrated that recognition
of murine MHC by human T cells plays an important role
in the pathogenesis of xGVHD in NSG mice. Specifically,
xGVHD following injection of hPBMC was delayed in NSG
mice lacking expression of MHC class II expression (NSG-Ab◦
mice) (20), while NSG mice lacking MHC class I expression
were resistant to xGVHD induced by injection of hPMBC (20).
These observations suggest that recognition of MHC class I
murine molecules by human CD8+ T cells is preponderant in
xGVHD. In accordance with these observations, Søndergaard
et al. nicely demonstrated that human CD8+ T cells were
sufficient and required for xGVHD induction, while injection
of purified CD4+ T-cells failed to induce xGVHD in NSG mice
(22). Further, these authors demonstrated that the CD28-B7.2
second signal was required for human T-cell proliferation and
xGVHD induction in NSG mice infused with hPBMC (22).
Interestingly, analyses by classical spectratyping showed that
TCRβ repertoire was diverse after hPBMC transplantation in
NSGmice (21, 22), suggesting that there was a high proportion of
non-TCR-specific driven T-cell proliferation in the pathogenesis
of xGVHD.
Here, we took advantage of recent techniques (such as RNA
sequencing (RNAseq), multicolor flow cytometry and deep TCRβ
sequencing) to further describe the pathogenesis of xGVHD
induced by injection of hPBMCs in NSG mice. In addition,
we compared xGVHD pathogenesis in classical NSG mice and
in NOD-scid IL-2Rγnull, HLA-A2/HHD (NSG-HLA-A2/HHD)
mice (expressing HLA-A0201 molecules and the human β2
microglobuline in addition to mouse MHC class 1 and class
2 molecules) (33, 34) in which xGVHD could better mimic
the clinical setting of allo-HCT in which human T cells are
activated through interaction with human, and not mouse, MHC
molecules.
MATERIAL AND METHODS
PBMCs Isolation and HLA-A Typing
Peripheral blood was obtained from healthy volunteers (aged
23–35 years old) after they signed a written informed consent
approved by our Ethical Committee. PBMCs were harvested
from peripheral blood by Ficoll-Paque (GE Healthcare, Freiburg,
Germany) gradient centrifugation. HLA-A typing was performed
by flow cytometry using an anti-HLA-A2 antibody (see next
sections for flow cytometry protocols) while the presence of
HLA-A0201 was confirmed by PCR.
Induction and Assessment of xGVHD in
NSG Mice
NSG or NSG-HLA-A2/HHD mice (The Jackson laboratory, Bar
Harbor, ME), aged from 8 to 10 weeks, were irradiated with
2.5Gy and given 24 h later an i.v. injection of 1 × 106 (in
some experiments) or 2 × 106 (in most experiments) hPBMCs
to induce xGVHD. GVHD severity was assessed by a scoring
system that incorporates four clinical parameters: weight loss,
posture (hunching), mobility and anemia as previously reported
(24). Each parameter received a score of 0 (minimum) to 2
(maximum). Mice were assessed for GVHD score thrice weekly
and monitored daily during the experiments. Mice reaching
a GVHD score of 6/8 were sacrificed in agreement with the
recommendation of our ethical committee. Final scores for dead
animals reaching the ethical limit score were kept in the data set
for the remaining time points (last value carried forward). All
experimental procedures and protocols used in this investigation
were reviewed and approved by the Institutional Animal Care
and Use Ethics Committee of the University of Liège, Belgium.
The “Guide for the Care and Use of Laboratory Animals,”
prepared by the Institute of Laboratory Animal Resources,
National Research Council, and published by the National
Academy Press, was followed carefully.
RNA Sequencing and Bioinformatics
Analysis
Five NSG and five NSG-HLA-A2/HHD mice were transplanted
with PBMCs from four non-HLA-A2 different donors (2 × 106
PBMCs iv, 24 h after 2.5Gy TBI), 3 out of 5 mice receiving
the PBMCs from a single donor for each mouse while the
two remaining animals received the PBMCs from the same
donor. One million of CD3+ cells were sorted from PBMCs
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of each donor by flow cytometry and preserved at −80◦C
in Tripure (Roche) while another million of sorted T cells
was stimulated in vitro with CD3/CD28 dynabeads (bead:cell
ratio 1:1, Invitrogen, Waltham, MA) in X-VIVO 15 (Lonza,
Verviers, Belgium). After 4 days of culture, 1 million of T cells
was collected from the stimulated cells and cryopreserved in
Tripure. At day 7 post-transplantation, mice were sacrificed
and 1 million of human CD3+ T cells were sorted from their
spleen (in all but one NSG-HLA-A2/HHD mice which died
due to irradiation). All sorted T cells were preserved at −80◦C
in Tripure until the day of RNA extraction. Total RNA was
isolated (RNeasy Mini Kit, Qiagen, Venlo, The Netherlands) and
used for poly(A) selection and Illumina Truseq stranded library
preparation following manufacturer’s instructions. Samples were
sequenced on the Illumina NextSeq500 to an average depth of
23.8 × 106 76-bp reads per sample. Reads alignment, processing
and counting were performed with the “RNA-seq Alignment
1.1.0” app from Illumina BaseSpace, reads were aligned to
the human genome (RefSeq UCSChg19) using STAR 2.5.0b,
novel transcript assembly and default settings. The average
read alignment rate was 99.2%. Differential expression, principal
component analyzes and hierarchical clustering heatmaps were
computed using DESeq2 1.16.1 in R (version 3.4.1) (35) on
genes having at least one read in at least one sample (19,846
out of 26,364 genes). Genes significantly up- or down-regulated
were defined as genes with a change in expression of at least
2-fold or 0.5-fold, respectively, and a FDR-adjusted p-value of
≤0.05. Gene set expression analyzes were performed in GSEA
software v3.0 (36) using the FPKM data, generated by the
RNA-seq Alignment app, as input (including all genes having
at least one read in at least one sample). The HALLMARK
gene sets (accessed on 04 September 2017) were used to
analyze the pathways differentially expressed between the four
different conditions. The costimulation by CD28 pathway was
analyzed using the gene set of the same name from REACTOME
(M17386, accessed on 18 September 2017), the TCR signaling was
analyzed using the signature of 165 genes described by Datlinger
et al. (37) (Supplemental Table 5), the Th1/Th2 pathway by
the BIOCARTA_TH1TH2_Pathway (M6705, accessed on 15
January 2018), the Th17 differentiation by the RORγt and
RORα signature genes set (38) (Supplemental Table 7) and the
Aurora kinase A by the PID_AURORA_A_PATHWAY (M242,
accessed on 30 January 2018). Analyses were performed with
1,000 permutations (phenotype type) for p-value calculation.
Default parameters were used. Gene sets with FDR (q-value)
≤ 0.25 were considered statistically significantly differentially
expressed.
Flow Cytometry
At the time of necropsy, peripheral blood (PB), spleen, bone
marrow (BM), liver and lungs were harvested and analyzed
by flow cytometry. PB was depleted of erythrocytes using
RBC lysis buffer (eBioscience, San-Diego, CA) according to
manufacturer’s instructions. Splenocytes were obtained by
crushing the spleen, and BM cells by flushing femurs and
tibiae. Lungs and liver infiltrating cells where obtained by
mincing and incubating the organs for 1 h in HBSS + 50µg/ml
DNase 1 (Roche, Basel, Switzerland) + 1 mg/ml collagenase
A (Roche). Digestions were stopped by washing twice with
PBS+EDTA 10mM, pH = 7.3, and mononuclear white blood
cells where collected by ficoll gradient centrifugation. Cells
from all organs were washed twice with PBS+3% FBS and
were counted with a Sysmex XS-800i R© before processing
with antibodies staining. The following antibodies specific
for human antigens were used: anti-CD45-APC (HI30);
anti-CD45-PECy7 (HI30); anti-CD45-PerCP (2D1, BD);
anti-CD4-eFluor450 (RPA-T4); anti-CD4-PerCP (SK3, BD);
anti-CD8-PECy7 (SK1, SONY); anti-CD8-BV510 (RPA-T8,
Biolegend, San-Diego, CA); anti-CD45RA-BV510 (HI100, BD);
anti-CD27-PE (M-T271, BD); anti-CD62L-APC-eFluor780
(DREG56), anti-CD25-BV421 (M-A251, BD); anti-HLA-DR-
APC-eFluor780 (LN3); anti-GRANZYME B-PE (GB11, BD);
anti-FOXP3-AlexaFluor488 (206D, Biolegend); anti-KI67-
AlexaFluor647 (B56, BD); anti-IL-17-APC (eBio64DEC17);
anti-IFNg-PECy7 (4S.B3); anti-TNF-α-APCCy7 (Mab11,
SONY); anti-IL-4-PE (MP4-25D2, SONY); anti-PD-1-APC-
eFluor780 (eBioJ105); anti-phosphoSTAT5-AlexaFluor647
(pY694, BD); and the following antibody specific for mouse
antigens was used: anti-CD45-FITC (30-F11, BD) (all from
eBioscience unless indicated otherwise). Cells (1.5–2 × 106
cells/sample), resuspended in 50 µl of PBS+3%FBS, were
incubated with surface antibodies for 20min at 4◦C in the dark
and washed twice with PBS+3% FBS. Intracellular staining for
FOXP3, KI67, GZMB and cytokines was performed by using
the FoxP3 Staining Buffer Set (eBioscience). For intracellular
cytokine staining, spleen homogenates were stimulated for 4 h
in RPMI supplemented with 10% FBS, penicillin (100 U/mL),
streptomycin (10 mg/mL) and in presence of PMA/ionomycin,
brefeldin A and monensin (Cell Stimulation Cocktail + Protein
Transport Inhibitors, eBioscience). For pSTAT5 staining, the
PerFix EXPOSE reagent kit (Beckman Coulter, Fullerton,
CA) was used as previously reported (39). Total cell count of
human CD45+ cells in blood were calculated based on the
absolute number of white blood cells (counted by using a
Sysmex XS-800i cell counter) and on the human cell chimerism
[frequency of human CD45+ cells among the total white
blood cell population (%humanCD45
++%mouseCD45
+)]. Data
were acquired on a FACS Canto II flow cytometer (Becton
Dickinson) and analyzed with the Flowjo software 7.0 (Tree
Star Inc., Ashland, OR). In gating strategies, regulatory T cells
(Treg) were defined as CD4+CD25+FOXP3+ while remaining
CD4+ T cells were termed conventional T cells (Tconv). Naïve
T cells were defined as CD45RA+CD27+, effector T cells
(TE) as CD45RA−CD27−, effector memory T cells (TEM) as
CD45RA−CD27+CD62L−, and central memory T cells (TCM)
as CD45RA−CD27+CD62L+.
TCR Repertoire Diversity
Spleens or lungs from 10 NSG or 10 NSG-HLA-A2/HHD
mice were pooled into a NSG and a NSG-HLA-A2/HHD
pool and were processed to stain human CD45, CD3, CD4
and CD8 antigens for flow cytometry sorting. A total of one
million of CD45+CD3+CD4+ and of CD45+CD3+CD8+ T
cells were sorted from each organ and each mouse strains, and
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from the hPBMC donor (collected the day of transplantation).
DNA was extracted immediately from these cells by using the
PureLink Genomic DNA Mini Kit (Invitrogen); 125 µg from
each samples were used for T-cell receptor β chain (TCRβ) deep
sequencing performed by Adaptive Biotechnologies (Seattle,
WA, USA).
Histology and Immunochemistry
Lungs and liver from mice sacrificed at day 14 after
transplantation were harvested, washed with PBS, fixed in
10% formalin (Sigma Aldrich) and routinely processed for
paraffin embedding. Five µm sections were stained with
hematoxylin-eosin (H&E) for histological examination.
Immunostaining was performed on 5-µm sections using a
BenchMark XT autostainer (Ventana Medical Systems, Tucson,
AZ, USA) for human CD3 (clone PS1; Novocastra/Leica,
Newcastle Upon Tyne, UK). Slides were assessed by using a
semiquantitative scoring system for abnormalities known to be
associated with GVHD, adapted from Blazar et al. (40). Fourteen
parameters were scored for lungs (perivascular inflammation,
peribronchiolar inflammation, interstitial infiltrate endothelitiis,
airway epithelial apoptosis, airway epithelial detachment,
alveolar edema, alveolar debris, alveolar damage, fibrosis,
hemorrhage eosinophilic crystals, bronchiolar epithelial
hyperplasia, and bronchiolar epithelial mucous production)
and 16 for the liver (portal tract expansion by inflammatory
cell infiltrate, lymphocytic infiltrate of bile ducts, bile periductal
inflammatory infiltrate, bile duct hyperplasia, ductopenia,
bile duct epithelial cell apoptosis, bile duct epithelial cell
sloughing, bile duct epithelial hyalinosis, vascular endotheliitis,
parenchymal apoptosis, hepatocyte degeneration/ballooning,
parenchymal microabscessses, parenchymal mitotic figures,
hepatocellular cholestasis hepatocellular steatosis, and fibrosis).
Each parameter was scored as follows: 0 indicates normal; 0.5,
focal and rare; 1, focal and mild; 2, diffuse and mild; 3, diffuse
and moderate; and 4, severe.
Serum Cytokine Levels
The concentration of human cytokines was determined in mice
serum, after 2-fold dilution, using a custom Magnetic Luminex
Performance Assay (R&D Systems, Minneapolis, MN, USA). The
experiments were performed according to the manufacturer’s
recommendation, and results were acquired on Bio-Plex System
and analyzed with Bio-Plex Manager Software 4.0 (Biorad
Laboratories) as previously reported (41).
GvL Effects and Bioluminescence Imaging
For GvL effect assessment, mice were co-injected with 1 million
luciferase-expressing THP-1 cells and 1 million hPBMC from
non-HLA-A0201 donor after 2.5Gy TBI. Twenty-one days
later, three non-transplanted NSG mice and all transplanted
NSG and NSG-HLA-A2/HHD mice were further injected
subcutaneously in the left flank with 1 million of THP-
1 cells in matrigel. Bioluminescence analyses were made as
previously reported (42). In brief, mice were injected i.p. with
3mg of D-luciferin (Promega, Madison, WI, USA) in PBS
and imaged 12min later. Tumor growth was evaluated by
measuring bioluminescence of THP-1 cell line transfected to
express the luciferase reporter gene by using the bioluminescent
IVIS imaging system (Xenogen-Caliper, Hopkinton, MA). Mice
were anesthetized using isoflurane (2.5% vaporized in O2).
For analysis, total photon flux (photons per second) was
measured from a fixed region of interest over the entire
abdomen using Living Image 2.60.1 and IgorPro software
(Wavemetrics).
Statistical Analyses
The Mann-Whitney test was used to compare flow-cytometry
data between two different groups. Comparisons between
GVHD score curves were made using the 2-way ANOVA
test. Survival curves were modeled using the Kaplan-Meier
methods. Comparisons between groups were made with the
log-rank test. Multivariate Cox models adjusted for weight,
female PBMC donor to male mouse, and age of mice at
transplantation were also performed. In order to determine
whether the survival differences between NSG and NSG-HLA-
A2/HHD mice injected with human PBMC were consistent with
different donors, meta-analyses of Hazard ratio obtained with
each different donor were performed using fixed effects models.
P-values < 0.05 were considered as statistically significant and
all P-values were 2-sided. Statistical analyses were carried out
with Graphpad Prism 5.0 (Graphpad Software, San Diego, CA,
USA) or with NCSS 11 (NCSS Statistical Software, LLC, Kaysville,
UT, USA).
Data Availability
RNA-Seq data have been deposited in the ArrayExpress database
at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession
number E-MTAB-6865. The datasets supporting the conclusions
of this article are included within this article and its additional
files.
RESULTS
Comparison of the Transcriptomes of T
Cells at Baseline, After in vitro Activation
and After Transplantation in NSG Mice
To gain insight into the mechanisms of T-cell expansion in NSG
and NSG-HLA-A2/HHDmice, we performed a RNA-sequencing
of T cells sorted from mouse spleens 7 days post-transplantation.
As controls, we analyzed the transcriptome of T cells sorted from
the same PBMCs used to transplant the animals, which were
either not stimulated (resting condition) or in vitro-stimulated
with CD3/CD28 beads (CD3CD28 condition).
While the gene expression profile of T cells from NSG and
NSG-HLA-A2/HHD mice were virtually identical, the greatest
changes of expression were observed between resting T cells
and T cells from all other conditions (Figures 1A,B). These
differences were confirmed by a hierarchical heatmap showing
that all mice samples clustered together and were more closely
related to CD3/CD28 than to unstimulated samples (Figure 1C).
These observations suggest that a main source of variation of T
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FIGURE 1 | RNA sequencing of T cells isolated from spleen of NSG and NSG-HLA-A2/HHD mice. RNA-sequencing was performed on T cells sorted from the spleen
of NSG and NSG-HLA-A2/HHD (NSG.A2 in figure) mice at day 7 post-transplantation, as well as on unstimulated T cells and CD3/CD28-stimulated T cells (n = 4–5 in
each condition). (A) Principal-component analysis performed using all genes having at least one read in at least one sample. (B) Gene expression (average of log2
normalized read counts) in every pairwise comparison between the different conditions. Colors indicate significant (FDR ≤ 0.05) upregulation (of at least 2-fold; red) or
downregulation (of at least 0.5-fold; blue) of expression in the comparison of the condition represented on the left vs. the condition represented on the bottom of the
panel. Numbers in plots indicate total genes upregulated (red) or downregulated (blue). (C) Heatmap of hierarchical clustering of the different samples. (D) Gene set
enrichment analyzes (GSEA) of the NSG vs. unstimulated T cells comparison. (E) GSEA of the NSG vs. unstimulated T cells comparison for TCR signaling,
costimulation, Th1Th2 differentiation, Th17 differentiation by the RORγt and RORα signature genes set and Aurora kinase A pathway comparisons.
cells after injection in mice is their activation through TCR and
CD28 pathways.
In order to confirm this hypothesis, we analyzed the variation
of specific pathways by gene set enrichment analyzes (GSEA)
in the NSG vs. unstimulated comparison. The HALLMARK
matrix of gene sets highlighted that 30 out of 50 gene
sets were significantly enriched in T cells from NSG mice
(Supplemental Table 1). Among these pathways, five were linked
to proliferation regulation (Figure 1D), six were associated
with metabolism, five with immune responses and four
with signaling pathways. Interestingly, the PI3K/AKT/mTOR
(detailed in Supplemental Table 2) and IL-2/STAT5 (detailed
in Supplemental Table 3) pathways were both upregulated,
supporting the hypothesis that T cell proliferation in NSG
mice is driven by IL-2 in addition to TCR stimulation and
co-stimulation signals. Comparable results were obtained in
the NSG-HLA-A2/HHD vs. unstimulated T cells comparison
(Supplemental Table 4).
As the HALLMARK matrix does not include gene sets for
TCR and costimulation pathways, we used a TCR signaling
signature recently described (37) (Supplemental Table 5), and
the co-stimulation by CD28 family gene set from REACTOME.
As hypothesized, we observed significant enrichment of genes
involved in each TCR and co-stimulation signaling after
injection in mice (Figure 1E). We next assessed whether T-
cell transplantation in NSG mice induced a Th polarization by
comparing the profile of genes expressed inNSG vs. unstimulated
T cells. We observed an upregulated expression of Th1 genes
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(IL2RA, IL12RB2, INFG, IL2, IL12RB1, and IL18) as well as
of the Th2 gene IL4 in T cells recovered from the spleens
while there was no upregulation of Th17 genes (Figure 1E and
Supplemental Tables 6,7). Recently, Aurora Kinase A (AURKA)
has been identified as promising target in the prevention of
GVHD (43). Therefore, we assessed whether this pathway was
altered in T cells expanding in NSG mice. As showed in
Figure 1E, the AURKA pathway was highly upregulated in NSG
mice, further supporting the physiological relevance of the NSG
model for the study of GVHD.
GSEA analysis of the NSG vs. CD3CD28 samples showed that
only the cholesterol homeostasis gene set of the HALLMARK
matrix was significantly differentially expressed (upregulated
in CD3CD28 samples). Regarding the other assessed gene
sets, we found no significant difference of expression between
both conditions for AURKA pathway, Th17 differentiation and
co-stimulation signaling while TCR signaling and TH1TH2
differentiation were found to be significantly upregulated
(FDR = 0.168 and 0.138, respectively) in NSG mice (data not
shown).
In summary, these data show that, in comparison to baseline,
T cells recovered from the spleen of mice 7 days after
transplantation had upregulated expression of genes involved in
cell proliferation, as well as in TCR, co-stimulatory, IL-2/STAT5,
mTOR, AURKA, and Th1 signaling.
Characterization of T Cells Recovered
From Mice 14 Days After hPBMC Infusion
Median proportion of T cells among human CD45 cells in the
spleen on day 14 after transplantation were 43% (34–45%) in
NSG and 47% (33–59%) in NSG-HLA-A2/HHD mice in case of
non-HLA-A2 donor (P = 0.35) and 54% (43–58%) in NSG and
64% (53–70%) in NSG-HLA-A2/HHD mice in case of HLA-A2
donor (P = 0.051).
NSG and NSG-HLA-A2/HHD Mice Infused With
Non-HLA-A2 hPBMC
Median CD4/CD8 ratios were comparable in NSG and in NSG-
HLA-A2/HHD mice and ranged between 2 and 3 in the blood,
spleen, lungs and liver and were above 4 in the bone marrow
(Figure 2A).
CD4+ T cells
The frequency of Treg among CD4+ T cells in the blood,
spleen, bone marrow as well as in xGVHD target organs in both
NSG and NSG-HLA-A2/HHD mice ranged between 12.4 and
0.6% (Figure 2B). The main subpopulations of CD4+ T cells
in the blood, spleen and bone marrows were TEM, followed
by TE while there was a relatively low frequency of TN and
TCM (Figures 2C,D). Remarkably, the proportions of TE were
significantly lower in the peripheral blood of NSGmice andNSG-
HLA-A2/HHDmice than in their lungs (P= 0.002 and P< 0.001,
respectively) or liver (P = 0.11 and P < 0.001, respectively),
demonstrating a higher frequency of effector T cells in xGVHD-
target organs (Figure 2D). Further, the proportions of CD4+ T
cells expressing PD-1 were significantly higher in the spleen of
NSG and NSG-HLA-A2/HHDmice than in their lungs (P= 0.03
and P = 0.09, respectively; Figure 2E).
Interestingly, the distribution of the different CD4+ T cell
subtypes in the blood, spleen, lungs and liver were similar
between NSG and NSG-HLA-A2/HHDmice.
In concordance with RNAseq analyses, assessment of the
production of cytokine by splenic human T cells after stimulation
by PMA/ionomycin demonstrated a TH1 profile (the majority of
the cells were INFγ+ while very few CD4+ T-cells were IL-4+ or
IL-17+; Figures 2F–I). Similarly, the majority of CD4+ T cells in
xGVHD target organs from NSG and NSG-HLA-A2/HHD mice
were positive for TNFα, INFγ or both (Figures 2H,I).
CD8+ T cells
The majority of CD8+ T cells present in NSG and NSG-HLA-
A2/HHDmice were TEM (Figures 2C,D). As observed for CD4+
T cells, the proportions of CD8+ TE were significantly lower in
the peripheral blood (5% in NSG mice and 6% in NSG-HLA-
A2/HHD mice) than in the lungs [18% in NSG mice (P < 0.001)
and 21% in NSG-HLA-A2/HHD mice (P = 0.003)] or the liver
[22% in NSG mice (P < 0.001) and 35% in NSG-HLA-A2/HHD
mice (P < 0.001)]. In contrast, there were significantly less naïve
CD8+ T cells in the liver than in the blood of NSG (2 vs. 16%,
P = 0.001) and NSG-HLA-A2/HHD mice (2 vs. 8%, P = 0.056).
Further, the proportions of CD8+ T cells expressing PD-1 were
significantly higher in the spleen of NSG (71%) and NSG-HLA-
A2/HHD (71%) mice than in their lungs [55% for NSG mice
(P = 0.03) and 50.4% for NSG-HLA-A2/HHD mice (P = 0.008);
Figure 2E].
Interestingly, there was a higher proportion of naïve CD8+
T cells in the blood of NSG than in the blood of NSG-HLA-
A2/HHD (16 vs. 8%, P = 0.007), suggesting higher CD8+ T-
cell differentiation in NSG-HLA-A2/HHD mice (Figure 2D).
In addition, there was a lower proportion of CD8+ T cells
INFγnegTNFαneg in the liver of NSG-HLA-A2/HHD mice than
in those from NSG mice (P = 0.016; Figure 2I).
Serum cytokine levels
In concordance with our flow-cytometry analyses, serum bioplex
analyses revealed high concentration of INFγ and to a lesser
extend of TNFα in the sera of each NSG andNSG-HLA-A2/HHD
mice, while there was a low concentration of IL-17 (Figure 2G).
NSG and NSG-HLA-A2/HHD Mice Infused With
HLA-A2 hPBMC
In contrast to what was observed with infusion of non-HLA-
A2 PBMC, median CD4/CD8 ratios were significantly higher in
NSG than in NSG-HLA-A2/HHD mice in each assessed organs
when HLA-A2 hPBMC were infused (Figure 3A). With this
exception, main findings seen with the infusion of non-HLA-A2
PBMC were also observed with the infusion of HLA-A2 PBMC:
Treg frequencies within the normal range (Figure 3B), higher
proportions of CD4+ and CD8+ TE in xGVHD target organs
than in the blood (Figure 3C), lower PD-1 expression in the
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FIGURE 2 | Differentiation and phenotype of human T cells in NSG and NSG-HLA-A2/HHD mice transplanted with non-HLA-A2 PBMCs. NSG and
NSG-HLA-A2/HHD (NSG.A2 in figure) mice were transplanted with HLA-A2− PBMCs and were sacrificed at day 14 to collect their organs and perform flow cytometry
analyzes. (A) CD4/CD8 ratio in indicated organs (11 mice/group). (B) Frequency of Treg in the different organs (11 mice/group). (C) Representative FACS plots and
gating strategy of the data shown in panel D. (D) Mean frequency of naive (TN, CD45RA+CD27+), effector (TE, CD45RA−CD27−), central memory (TCM,
CD45RA−CD27+CD62L+) and effector memory (TEM, CD45RA−CD27+CD62L−) T cells (11 mice/group). (E) Frequency of PD-1+ T cells (4–5 mice/group).
(F) Frequency of IFNγ+, TNF-α+, IFNγ+TNF-α+, IL-4+, and IL-17+ T cells in spleen (11 mice/group). (G) Serum concentration of IFNγ, TNF-α and IL-17 cytokines,
assessed by bioplex (6–7 mice/group). (H) Representative FACS plots and gating strategy of the data shown in panel I. (I) Mean frequency of IFNγ−TNF-α+,
IFNγ+TNF-α+, IFNγ+TNF-α−, IFNγ−TNF-α−, and IL-17+ IFNγ+ T cells (4–5 mice/group). Data in A, B, E, F, and G show the median, 25 and 75th percentiles of the
distribution (boxes), and whiskers extend to the 5 and 95th percentiles.
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FIGURE 3 | Differentiation and phenotype of human T cells in NSG and NSG-HLA-A2/HHD mice transplanted with HLA-A2 PBMCs. NSG and NSG-HLA-A2/HHD
(NSG.A2 in figure) mice were transplanted with HLA-A2+ PBMCs and were sacrificed at day 14 to collect their organs and perform flow cytometry analyzes.
(A) CD4/CD8 ratio in indicated organs (11–12 mice/group). (B) Frequency of Treg in the different organs (11–12 mice/group). (C) Mean frequency of naive (TN,
CD45RA+CD27+), effector (TE, CD45RA−CD27−), central memory (TCM, CD45RA−CD27+CD62L+) and effector memory (TEM, CD45RA−CD27+CD62L−) T cells
(11–12 mice/group). (D) Frequency of PD-1+ T cells in spleen (5 mice/group). (E) Frequency of IFNγ+, TNF-α+, IFNγ+TNF-α+, IL-4+, and IL-17+ T cells in spleen
(11 mice/group). (F) Mean frequency of IFNγ−TNF-α+, IFNγ+TNF-α+, IFNγ+TNF-α−, IFNγ−TNF-α−, and IL-17+ IFNγ+ T cells (5 mice/group). Data in A, B, D, and
E show the median, 25 and 75th percentiles of the distribution (boxes), and whiskers extend to the 5 and 95th percentiles (*p < 0.05, **p < 0.005, ***p < 0.0005).
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spleen than in the lungs (Figure 3D), and predominant Th-1
profile (Figures 3E,F).
Interestingly, there was a higher proportion of naïve CD8+
T cells in the blood (P = 0.027) and in the lungs (P = 0.01)
of NSG than in the blood of NSG-HLA-A2/HHD, suggesting
higher CD8+ T-cell differentiation in NSG-HLA-A2/HHD mice
(Figure 3C). There was also a higher proportion of CD8+ TCM
in the bone marrow of NSG-HLA-A2/HHDmice (P = 0.008).
FIGURE 4 | T-cell repertoire of CD4+ and CD8+ T cells in NSG and NSG-HLA-A2/HHD mice. NSG and NSG-HLA-A2/HHD (NSG.A2 in figure) mice were
transplanted with HLA-A2− PBMCs and were sacrificed at day 14 to perform TCRβ sequencing on T cells sorted and pooled (10 mice pooled/condition) from their
spleen and lungs. (A) Productive clonality of CD4+ and CD8+ T cells sorted from donor PBMCs (before infusion to mice), spleen and lungs of NSG and
NSG-HLA-A2/HHD mice. (B,C) Venn diagram comparing the identity of clonotypes between indicated samples (D,E) Correlations of clonotypes productive frequency
between indicated samples.
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TCR Repertoire of Human T Cells
Infiltrating the Spleen and the Lungs of
NSG and NSG-HLA-A2/HHD Mice
Looking at the repartition of TCRβ families, as previously
reported by us and by others in NSG mice using classical
spectratyping technique (21, 22), TCRβ repertoire appeared
highly polyclonal in the spleen and lungs of each NSG and NSG-
HLA-A2/HHDmice (Supplemental Figure 1). However, specific
TCR sequencing analyses demonstrated that the productive
clonality (a normalized score based on diversity and sample
entropy for which values near 0 represent more polyclonal
samples and values near 1 represent more oligoclonal samples)
was markedly higher (meaning less diversity) in each CD4+ and
CD8+ T cells in the spleen on day 14 after transplantation than
at the time of infusion. This evidences dramatic TCRβ repertoire
narrowing after transplantation (Figure 4A).
As previously well-established, TCR diversity was lower in
CD8+ than in CD4+ T cells at infusion (44), and this remained
the case on day 14 after transplantation. Interestingly, the
productive clonality was comparable in the spleen and in the
lungs on day 14 after transplantation but was slightly lower
(meaning more diversity) in NSG-HLA-A2/HHD than in NSG
mice suggesting that additional antigens were recognized by
donor CD8+ T cells in NSG-HLA-A2/HHD mice. In contrast,
productive clonality was comparable in CD4+ T cells from NSG
and NSG-HLA-A2/HHDmice (Figure 4A).
We next compared the identity of clonotypes between
hPBMCs before infusion and in spleen post-infusion. As showed
in the Figure 4B, we observed a very low overlap of their identity
for each CD4+ and CD8+ T cells. This, together with the
dramatic decrease of TCR diversity post-infusion, demonstrates
that xGVHD is caused by a fraction of T cells having a low
frequency in donor PBMCs (and therefore undetected in these
samples) which subsequently expand in mouse organs.
We next compared the identity of clonotypes between organs
and mouse types. As shown in the Figures 4C,D, we observed
a low overlap of clonotype identity between the CD4+ and
CD8+ T cells harvested from the spleen of NSG vs. NSG-HLA-
A2/HHD mice. In contrast, there was some overlap between
clonotypes identity observed in the spleens vs. the lungs in
both mouse strains. Finally, no correlation of CD8+ T cell
clonotypes frequency was observed between donor PBMCs and
in spleen post infusion, either in NSG or NSG-HLA-A2/HHD
mice (Figure 4E).
These data show that expression of HLA-A0201 impacted the
repertoire of T cells causing xGVHD, and that a proportion of
T cells with similar clonotypes were present in the spleen and
xGVHD target organs.
Survival and xGVHD Scores
We next investigated whether the expression of HLA-A0201 by
NSG mice not only impacted the repertoire of T cells causing
FIGURE 5 | Higher lethality and severity of xGVHD in NSG-HLA-A2/HHD mice transplanted with non-HLA-A2 PBMCs. NSG and NSG-HLA-A2/HHD (NSG.A2 in
figure) mice were transplanted with 2 × 106 (A–D) or 1 × 106 (E,F) HLA-A2− PBMCs intravenously. (A) Pooled survival rates from the three different experiments
[n = 23 (NSG) vs. 20 (NSG-HLA-A2/HHD)]. (B,C) Pooled xGVHD scores (B) and weight loss (C) from the three different experiments. (D) Meta-analyses of Hazard
ratio obtained with each different donor. (E,F) Pooled survival rates and xGVHD scores from two different experiments (n = 22 (NSG) vs. 21 (NSG-HLA-A2/HHD).
(G) Day 14 human cell chimerism and absolute counts in NSG (n = 11) and NSG-HLA-A2/HHD (n = 11) mice transplanted with 2 × 106 PBMCs. (H) Day 14 human
cell chimerism and absolute counts in NSG (n = 20) and NSG-HLA-A2/HHD (n = 13) mice transplanted with 1 × 106 PBMCs. Data in G and H show the median, 25
and 75th percentiles of the distribution (boxes), and whiskers extend to the 5 and 95th percentiles (*p < 0.05, **p < 0.005, ***p < 0.0005).
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xGVHD but also exacerbated xGVHD. We first compared
xGVHD in NSG and NSG-HLA-A2/HHD mice transplanted
with 2 × 106 hPBMCs from non-HLA-A2 donor after 2.5Gy
irradiation. As shown in Figures 5A–C, xGVHD lethality and
severity were higher in NSG-HLA-A2/HHD than in NSG mice.
The higher lethality was consistent in the three independent
experiments and confirmed in a multivariate Cox regression
model adjusted for weight, female PBMC donor to male mouse,
and age of mice at transplantation (HR = 1.8, 95% CI 1.2–
2.8, P = 0.007; Figure 5D). When mice were transplanted with
1 × 106 hPBMCs, xGVHD lethality and severity were also
significantly higher in NSG-HLA-A2/HHD than in NSG mice
(Figures 5E,F).
We next hypothesized that in the case of NSG-HLA-A2/HHD
mice injected with HLA-A2 hPBMC, human T cells could react
against host cells expressing mouse peptide antigens bound to
HLA-A2, as suggested by Patton et al. (45). We indeed observed
a slightly more severe xGVHD in NSG-HLA-A2/HHDmice than
in NSG mice after infusion of 2 × 106 hPBMCs from HLA-A2
donors (Figure 6A).
Human Cell Expansion, Infiltration and Histologic
xGVHD
In mice transplanted with 2 × 106 hPBMCs from non-
HLA-A2 donor, there were higher absolute counts of human
hematopoietic cells in the blood of NSG-HLA-A2/HHD
mice than in the blood of NSG mice (P = 0.041) while
human chimerism levels were high (median > 90%) in each
NSG and NSG-HLA-A2/HHD mice (Figure 5G). Comparable
findings were made with HLA-A2 donors (Figure 6B). In
mice transplanted with 1 × 106 hPBMCs from non-HLA-A2
donor, there was a trend for higher absolute counts of human
hematopoietic cells in the blood of NSG-HLA-A2/HHD mice
than in the blood of NSG mice (P = 0.25), while human
chimerism levels were significantly higher NSG-HLA-A2/HHD
than in NSG mice P = 0.013; Figure 5H).
Typical histologic signs of GVHD (such as apoptotic bodies
or bile plugs) were found in the liver and lungs of each NSG and
NSG-HLA-A2/HHD mice while histological GVHD scores were
comparable in NSG and NSG-HLA-A2/HHD mice irrespective
of the HLA-A2 positivity or not of the donor (Figures 7, 8).
GvL Effects in NSG and NSG-HLA-A2/HHD
Mice
We finally assessed whether the more severe xGVHD observed
in NSG-HLA-A2/HHD mice translated to higher GvL effects.
Since THP-1 cells are HLA-A0201 positive (46, 47), we performed
these experiments with hPBMC from non-HLA-A2 donor in
order to have a similar target for xGVHD and GvL. In brief,
NSG and NSG-HLA-A2/HHD mice were co-transplanted with
3 million of THP-1 cells, transfected to express the luciferase
gene, and 1 million of human PBMCs (Figure 9A). Because very
low levels of bioluminescence were observed at day 20, probably
due to the elimination of THP-1 cells by hPBMCs, mice received
a second injection of THP-1-luc cells, this time administered
subcutaneously inmatrigel, at day 21. As control, three additional
NSG mice also received this subcutaneous injection without
FIGURE 6 | XGVHD in NSG-HLA-A2/HHD mice transplanted with HLA-A2+
donors. NSG and NSG-HLA-A2/HHD (NSG.A2 in figure) mice received
sublethal total body irradiation (2.5Gy) and were infused 24 h later with 2 ×
106 human PBMCs intravenously. PBMCs were isolated from HLA-A2+
healthy donors. (A) Survival, xGVHD scores and weight loss comparison of
NSG and NSG-HLA-A2/HHD mice transplanted with three different HLA-A2+
donors (in three independent experiments). (B) Day 14 total cell count of
human CD45+ cells in blood, calculated based on the absolute number of
white blood cells (counted by using a Sysmex XS-800i cell counter) and on the
frequency of human CD45+ cells among the total white blood cell population
(%humanCD45
+ + %mouseCD45
+). Data show the median, 25 and 75th
percentiles of the distribution (boxes), and whiskers extend to the 5 and 95th
percentiles (*p < 0.05, ***p < 0.0005).
Frontiers in Immunology | www.frontiersin.org 11 August 2018 | Volume 9 | Article 1943
Ehx et al. xGVHD Pathogenesis in NSG and NSG-HLA-A2/HHD
FIGURE 7 | Histological analyses in NSG and NSG-HLA-A2/HHD mice transplanted with non-HLA-A2 PBMCs. NSG and NSG-HLA-A2/HHD (NSG.A2 in figure) mice
received sublethal total body irradiation (2.5Gy) and were infused 24 h later either with 2 × 106 human PBMCs intravenously. PBMCs were isolated from HLA-A2−
healthy donors and experiment was repeated twice with different donors of PBMCs. Mice were sacrificed at day 14 to collect their organs. (A) Histopathological
evaluation of GVHD score in lungs and liver. Black arrows show apoptotic bodies, red arrows show mitosis and orange arrows show bile plugs. Panels on the right
show the comparison of 7–8 mice/group. (B) Histological quantification of human CD3+ cells (stained in brown) infiltration in lungs and liver of NSG and
NSG-HLA-A2/HHD mice. Panels on the right show the comparison of 7–8 mice/group. Data show the median, 25 and 75th percentiles of the distribution (boxes), and
whiskers extend to the 5 and 95th percentiles.
FIGURE 8 | Histological analyses in NSG and NSG-HLA-A2/HHD mice transplanted with HLA-A2 PBMCs. NSG and NSG-HLA-A2/HHD (NSG.A2 in figure) mice
received sublethal total body irradiation (2.5Gy) and were infused 24 h later with 2 × 106 human PBMCs intravenously. PBMCs were isolated from HLA-A2+ healthy
donors. Mice were sacrificed at day 14 to collect their organs. (A) Histological quantification of human CD3+ cells (stained in brown) infiltration in lungs and liver of
NSG and NSG-HLA-A2/HHD mice. Panels on the right show the comparison of 7–8 mice/group. (B) Histopathological evaluation of GVHD score in lungs (top panel)
and liver (bottom panel). Data show the median, 25 and 75th percentiles of the distribution (boxes), and whiskers extend to the 5 and 95th percentiles.
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FIGURE 9 | Higher graft-versus-leukemia effect in NSG-HLA-A2/HHD mice. NSG and NSG-HLA-A2/HHD (NSG.A2 in figure) mice received sublethal total body
irradiation (2.5Gy) and were infused 24 h later with 1 × 106 of human PBMCs and 3 million of THP-1-luc cells intravenously. (A) At day 21, all the mice transplanted at
day 0 (14 NSG and 13 NSG-HLA-A2/HHD) as well as four additional untransplanted NSG mice received a subcutaneous injection of 1 million of THP-1-luc cells in
matrigel. Experimental design, representative images of bioluminescence at day 41 post-transplantation and comparison of luminescence are shown. (B) In a
repetition of the first experiment, mice received only the intravenous injection of THP-1-luc cells [n = 4 (THP-1 only), 9 (NSG) and 8 (NSG-HLA-A2/HHD)]. Experimental
design, representative images of bioluminescence at day 35 post-transplantation and comparison of luminescence are shown. Actual images of one representative
mouse from each group are shown with Y-axis indicating photon flux (photons/s). Region of interest were drawn over the entire tumors (A) or over the entire body of
each mouse (B). Data show median values with interquartile range (*p < 0.05).
having received PBMCs or THP-1 cells previously. Twenty
days later, bioluminescence was again monitored and we could
observe that the tumor burden was significantly reduced in
NSG mice transplanted with PBMCs in comparison with control
mice, showing that human PBMCs eliminated THP-1 cells
subsequently to GvL effects. Interestingly, the tumor burden was
even more reduced in NSG-HLA-A2/HHDmice.
In a second experiment, and because luminescence of THP-
1 cells could be still observed at day 20, we did not transplant
additional THP-1 cells subcutaneously at day 21 (Figure 9B). At
day 35, we observed an overall reduction of bioluminescence
in NSG-HLA-A2/HHD mice in comparison with NSG mice,
confirming the result of the first experiment.
DISCUSSION
The aim of the current study was to further describe the
pathogenesis of xGVHD induced by injection of hPBMCs in
classical NSG mice and to assess the impact of the expression
of HLA-A0201 by NSG mice cells on xGVHD and GvL effects.
For the later, we reasoned that the expression of HLA-A0201 by
mouse cells might serve as an allogeneic antigen (in addition
to xenogeneic antigens) in case of transplantation with cells
from non-HLA-A0201 donor and might better present mouse
peptide antigens bound to HLA-A2 to T cells from HLA-A0201
hPBMC donors. In addition, in case of assessment of GvL effects
against the leukemic THP-1 cells, there were major antigens
(HLA-A0201) shared by mouse and human leukemic cells in
case of transplantation of hPBMC from a non-HLA-A2 donor,
mimicking what is happening in patients in whom GVHD
and GvL effects are frequently mediated in part toward similar
antigens (48).
Using RNAseq analyses on T cells harvested on day 7 after
transplantation we observed some similar gene activation
patterns in T cells injected in mice and in T cells stimulated in
vitro with CD3/CD28. This observation explains prior reports
demonstrating that lack of expression of murine MHC-class 1
or MHC-class 2 dramatically decreased T-cell proliferation (20),
while co-stimulation blockade with CTLA-4-Ig administration
inhibited T-cell expansion and prevented/treated xGVHD,
demonstrating that CD28–CD80/CD86 interactions were
necessary for xGVHD (22). In addition to upregulated expression
of genes involved in cell proliferation, as well as in TCR, co-
stimulatory, IL-2/STAT5, PI3K/AKT/mTOR signaling (49), and
Aurora kinase A pathway RNAseq analyses demonstrated the
upregulation of TH1 (but not TH17) genes in T cells harvested in
NSG mice in comparison to baseline T cells. Importantly, these
data correlate well with a recent transcriptomic study performed
in non-human primate demonstrating that alloreactive T
cells in acute GVHD are specifically characterized by (i) the
overexpression of Aurora kinase A, (ii) the upregulation of
pathways implicated in proliferation and effector function,
and (iii) a Th1-over-Th17-skewed immune response (43). The
relevance of aurora kinase A in xGVHD of NSG mice is further
supported by another recent study showing that its inhibition
leads to a significant amelioration of survival (50). Altogether
these data support the huPBMCs-infused NSG mice as robust
model of human GVHD physiopathology.
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Flow cytometry analyses of T cells harvested from the spleen
of NSG and NSG-HLA-A2/HHD mice were consistent with
RNAseq data and showed that, on day 14 after transplantation,
most T cells were either TEM or TE (in concordance with the
upregulation of the genes implicated in activation/proliferation
observed in RNAseq analyses) and produced the TH1 (or TC1)
cytokines INFγ and TNFα (or both). This observation is in
line with prior reports showing the efficacy of therapy blocking
TNFα for xGVHD prevention in NSG mice (20), despite a
recent study unraveled a “Treg promoting role” for TNFα trough
TNFR2 stimulation (51). Also, in concordance with the lack of
Th17 gene upregulation observed in RNAseq analysis in T cells
harvested from mice spleen on day 7, day 14 flow cytometry
analyses demonstrated that only a low percentage of CD4+ T cells
expressed IL-17. Further, most of these CD4+IL-17+ T-cells also
secreted INFγ.
In concordance with the observation that T-cell proliferation
in both NSG andNSG-HLA-A2/HHDmice is dependent on TCR
signaling, specific clonotypes analyses demonstrated dramatically
decreased TCR diversity in CD4+ and CD8+ T cells harvested
in the spleen or lungs of NSG or NSG-HLA-A2/HHD mice on
day 14 after transplantation in comparison to TCR diversity at
infusion. Further, there was a very low overlap for each CD4+
and CD8+ T cells between clonotypes at infusion and after
transplantation. This demonstrates that xGVHD is caused by T
cells having a low frequency in donor PBMCs (and therefore
mostly undetected in these samples) which subsequently expand
in mice.
Interestingly, there was a good correlation between the
frequencies of specific CD8+ T-cell clones in the spleen and in
the lungs on day 14 after infusion. This suggests that the xGVHD
reaction is at least in part systemic and not (always) restricted to
one specific organ. Interestingly, the CD8+ T cell TCR diversity
was higher in NSG-HLA-A2/HHD than in NSG mice suggesting
that additional antigens were recognized by donor CD8+ T
cells in NSG-HLA-A2/HHD (in comparison to NSG) mice.
Despite the significant correlation between specific CD8+ T-cell
clonotype frequencies in the spleen and in the lungs of treated
animals, we observed that the T-cell sub-phenotypes were distinct
in the spleen and in xGVHD target organs. Specifically, T cells
infiltrating the lungs or the liver had more frequently a TE but
less frequently a naïve phenotype than those from the spleen.
In addition to its impact on T-cell repertoire, we observed
that HLA-A0201 expression by NSG promoted CD8+ T-cell
expansion and exacerbated xGVHD. These results are in line
with a prior observation showing that after injection of purified
hematopoietic stem cells, NSG-HLA-A2/HHD but not NSG
mice developed xGVHD (45). Finally, as observed in humans
in which there is a strong correlation between GVHD and
GvL effects, we observed enhanced GvL effects in NSG-HLA-
A2/HHD mice. Altogether, these results show that HLA-A0201
molecules participate to the presentation of antigens to allogeneic
T cells and therefore that hPBMC-infused NSG-HLA-A2/HHD
mice could serve as model of combined xeno and allogeneic
GVHD.
In conclusion, our data demonstrate that the pathogenesis
of xGVHD shares important features with human GVHD
such as TCR/co-stimulatory-mediated expansion of selected T-
cell clones that acquire mainly a Th1/Tc1 profile (52). This
strengthens the robustness of this platform to study the impact
of various therapeutic agents on GVHD. Further, our data show
that NSG-HLA-A2/HHDmice could serve as model of combined
xeno and allogeneic GVHD/GvL effects.
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